Mineralys Therapeutics, Inc.
$30.07
▲
2.12%
2026-04-21 08:11:01
mineralystx.com
NMS: MLYS
Explore Mineralys Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.52 B
Current Price
$30.07
52W High / Low
$47.65 / $12.59
Stock P/E
—
Book Value
$7.93
Dividend Yield
—
ROCE
-26.38%
ROE
-36.91%
Face Value
—
EPS
$-2.29
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
76
Beta
0.69
Debt / Equity
—
Current Ratio
43.76
Quick Ratio
43.76
Forward P/E
-14.55
Price / Sales
—
Enterprise Value
$1.54 B
EV / EBITDA
-9.01
EV / Revenue
—
Rating
None
Target Price
$49.38
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CollPlant Biotechnologies Ltd. | $0.37 | — | $5.15 M | — | -141.54% | -1.18% | $4.98 / $0.27 | $0.47 |
| 2. | AC Immune SA | $2.98 | — | $303.29 M | — | -115.62% | -89.65% | $4 / $1.45 | $0.56 |
| 3. | Exelixis, Inc. | $46.57 | 16.78 | $11.84 B | — | 36.6% | 35.53% | $49.62 / $33.76 | $8.23 |
| 4. | Ovid Therapeutics Inc. | $2.89 | — | $381.12 M | — | -29.75% | -17.51% | $3.1 / $0.27 | $1 |
| 5. | Coya Therapeutics, Inc. | $4.99 | — | $112.13 M | — | -51.17% | -51.39% | $7.75 / $3.71 | $2.06 |
| 6. | CDT Equity Inc. | $3.35 | — | $16.81 M | — | 230.89% | 491.09% | $3,030 / $2.6 | $83.78 |
| 7. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -38.28 M | -41.13 M | -46.75 M | -44.45 M | -51.77 M | — |
| Net Profit | -32.23 M | -36.93 M | -43.27 M | -42.21 M | -48.95 M | — |
| EPS in Rs | -0.39 | -0.45 | -0.52 | -0.51 | -0.59 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -170.6 M | -192.4 M | -84.66 M | -31.48 M |
| Net Profit | -154.65 M | -177.81 M | -71.9 M | -29.8 M |
| EPS in Rs | -1.88 | -2.16 | -0.87 | -0.36 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 661.81 M | 205.9 M | 251.64 M | 114.44 M |
| Total Liabilities | 15.11 M | 14.65 M | 10.48 M | 166.71 M |
| Equity | 646.69 M | 191.26 M | 241.15 M | -52.27 M |
| Current Assets | 661.39 M | 205.35 M | 249.1 M | 112.81 M |
| Current Liabilities | 15.11 M | 14.65 M | 10.48 M | 8.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -142.42 M | -166.31 M | -81.17 M | -29.22 M |
| Investing CF | -389.75 M | 114.96 M | -160.47 M | -21.76 M |
| Financing CF | 591 M | 116.14 M | 203.25 M | 128.02 M |
| Free CF | -142.43 M | -166.41 M | -81.17 M | -29.22 M |
| Capex | -0.01 M | -0.1 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -147.31% | -141.28% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.